84,844 XNAS Volume
XNAS 21 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Kok Thay Lim | Ten Percent Owner | 24 Jan 2025 | 652,981 | 0 | - | - | Warrants (Right to Buy) | ||
| Kok Thay Lim | Ten Percent Owner | 24 Jan 2025 | 535,274 | 0 | - | - | Warrants (Right to Buy) | ||
| Kok Thay Lim | Ten Percent Owner | Other type of transaction at price $ 0.00 per share. | 24 Jan 2025 | 652,981 | 652,981 | - | - | Warrants (Right to Buy) | |
| Kok Thay Lim | Ten Percent Owner | Other type of transaction at price $ 0.00 per share. | 24 Jan 2025 | 652,981 | 0 | - | - | Warrants (Right to Buy) | |
| Kok Thay Lim | Ten Percent Owner | Other type of transaction at price $ 0.00 per share. | 24 Jan 2025 | 535,274 | 535,274 | - | - | Warrants (Right to Buy) | |
| Kok Thay Lim | Ten Percent Owner | Other type of transaction at price $ 0.00 per share. | 24 Jan 2025 | 535,274 | 0 | - | - | Warrants (Right to Buy) | |
| Kok Thay Lim | Ten Percent Owner | 24 Jan 2025 | 652,981 | 6,335,630 | - | 2.1 | 1,351,671 | Class A Common Stock | |
| Kok Thay Lim | Ten Percent Owner | 24 Jan 2025 | 535,274 | 5,682,649 | - | 2.1 | 1,108,017 | Class A Common Stock | |
| Peter H. Diamandis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2024 | 84,746 | 416,459 | - | - | Stock Option (Right to Buy) | |
| Richard J. Berman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2024 | 84,746 | 202,857 | - | - | Stock Option (Right to Buy) | |
| Richard J. Berman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2024 | 67,416 | 67,416 | - | 0 | Class A Common Stock | |
| Dean C. Kehler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2024 | 67,416 | 303,482 | - | 0 | Class A Common Stock | |
| Dean C. Kehler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2024 | 84,746 | 362,524 | - | - | Stock Option (Right to Buy) | |
| Peter H. Diamandis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2024 | 67,416 | 1,374,482 | - | 0 | Class A Common Stock | |
| Peter H. Diamandis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2024 | 84,746 | 362,524 | - | - | Stock Option (Right to Buy) | |
| Geoffrey Shiu Fei Ling | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2024 | 67,416 | 67,416 | - | 0 | Class A Common Stock | |
| Geoffrey Shiu Fei Ling | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2024 | 84,746 | 1,334,746 | - | - | Stock Option (Right to Buy) | |
| Diane L. Parks | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2024 | 67,416 | 303,482 | - | 0 | Class A Common Stock | |
| Diane L. Parks | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2024 | 84,746 | 362,524 | - | - | Stock Option (Right to Buy) | |
| Peter H. Diamandis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2024 | 67,416 | 201,723 | - | 0 | Class A Common Stock | |
| Richard Berman J. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Aug 2024 | 118,111 | 118,111 | - | - | Stock Option Grant (Right to Buy) | |
| Kok Thay Lim | Ten Percent Owner | Other type of transaction at price $ 0.00 per share. | 15 Jul 2024 | 1,350,000 | 1,350,000 | - | - | Warrants (Right to Buy) | |
| Kyle Fletcher | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.10 per share. | 13 Apr 2024 | 20 | 21,085 | - | 4.1 | 82 | Class A Common Stock |
| Robert J. Hariri | Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.11 per share. | 13 Apr 2024 | 1,154 | 2,855,889 | - | 4.1 | 4,743 | Class A Common Stock |
| Kyle Fletcher | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.68 per share. | 15 Mar 2024 | 617 | 21,105 | - | 5.7 | 3,505 | Class A Common Stock |
| Kok Thay Lim | Ten Percent Owner | Other type of transaction at price $ 0.00 per share. | 13 Mar 2024 | 300,000 | 300,000 | - | - | Warrants (Right to Buy) | |
| Robert J. Hariri | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2024 | 2,937,788 | 2,937,788 | - | - | Stock Option Grant (Right to Buy) | |
| Fletcher Kyle | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2024 | 164,171 | 164,171 | - | - | Stock Option Grant (Right to Buy) | |
| Kilcoyne Adrian | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2024 | 205,213 | 205,213 | - | - | Stock Option Grant (Right to Buy) | |
| Fletcher Kyle | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.43 per share. | 16 Feb 2024 | 39,571 | 217,228 | - | 0.4 | 17,174 | Class A Common Stock |
| Adrian Kilcoyne | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.43 per share. | 16 Feb 2024 | 52,762 | 1,122,238 | - | 0.4 | 22,899 | Class A Common Stock |
| Kok Thay Lim | Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 12 Jan 2024 | 5,352,746 | 5,352,746 | - | - | Warrants (Right to Buy) | |
| Kok Thay Lim | Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.25 per share. | 12 Jan 2024 | 21,410,983 | 51,473,762 | - | 0.2 | 5,331,335 | Class A Common Stock |
| Thay Lim Kok | Ten Percent Owner | Other type of transaction at price $ 0.00 per share. | 12 Jan 2024 | 6,529,818 | 6,529,818 | - | - | Warrants (Right to Buy) | |
| Thay Lim Kok | Ten Percent Owner | Other type of transaction at price $ 0.00 per share. | 12 Jan 2024 | 6,529,818 | 0 | - | - | Warrants (Right to Buy) | |
| Kok Thay Lim | Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 12 Jan 2024 | 16,500,000 | 16,500,000 | - | - | Warrants (Right to Buy) | |
| Adrian Kilcoyne | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2023 | 875,000 | 1,175,000 | - | 0 | Class A Common Stock | |
| Robert J. Hariri | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.71 per share. | 13 Apr 2023 | 11,540 | 10,148,310 | - | 0.7 | 8,241 | Class A Common Stock |
| Kyle Fletcher | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.72 per share. | 13 Apr 2023 | 201 | 256,799 | - | 0.7 | 144 | Class A Common Stock |
| Robert J. Hariri | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.83 per share. | 27 Mar 2023 | 2,084,854 | 10,159,850 | - | 0.8 | 1,739,394 | Class A Common Stock |
| Robert J. Hariri | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2023 | 2,084,854 | 2,084,854 | - | - | Warrants (Right to Buy) | |
| Kyle Fletcher | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.63 per share. | 15 Mar 2023 | 2,170 | 257,000 | - | 0.6 | 1,365 | Class A Common Stock |
| Adrian Kilcoyne | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2023 | 300,000 | 300,000 | - | - | Class A Common Stock | |
| Kyle Fletcher | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2023 | 225,000 | 259,170 | - | - | Class A Common Stock | |
| Peter H. Diamandis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.28 per share. | 10 Feb 2023 | 1,071,000 | 1,107,145 | - | 0.3 | 299,880 | Class A Common Stock |
| Peter H. Diamandis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 1,071,000 | 2,660,136 | - | - | Stock Option (Right to Buy) | |
| Robert J. Hariri | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 1.72 per share. | 30 Nov 2022 | 10,000 | 8,074,996 | - | 1.7 | 17,175 | Class A Common Stock |
| Robert J. Hariri | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 1.71 per share. | 29 Nov 2022 | 40,000 | 8,064,996 | - | 1.7 | 68,400 | Class A Common Stock |
| Robert J. Hariri | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 1.74 per share. | 28 Nov 2022 | 40,000 | 8,024,996 | - | 1.7 | 69,600 | Class A Common Stock |
| John Sculley | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Aug 2022 | 768,594 | 0 | - | - | Stock Option (Right to Buy) | |
| John Sculley | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.28 per share. | 26 Aug 2022 | 768,594 | 804,739 | - | 0.3 | 215,206 | Class A Common Stock |
| Robert J. Hariri | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.87 per share. | 24 Aug 2022 | 119,073 | 7,984,996 | - | 2.9 | 341,740 | Class A Common Stock |
| Robert J. Hariri | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Aug 2022 | 119,073 | 230,287 | - | - | Stock Option (Right to Buy) | |
| Robin L. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2022 | 250,000 | 250,000 | - | - | Stock Option (Right to Buy) | |
| Robin L. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2022 | 800,000 | 800,000 | - | - | Stock Option (Right to Buy) | |
| Robert J. Hariri | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Apr 2022 | 131,234 | 7,865,923 | - | - | Class A Common Stock | |
| Robert J. Hariri | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Apr 2022 | 384,801 | 384,801 | - | - | Stock Option (Right to Buy) | |
| Andrew Pecora | President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2021 | 2,469,282 | 2,469,282 | - | - | Stock Option (Right to Buy) | |
| Beloo Mirakhur | EVP, Clinical Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Sep 2021 | 125,000 | 125,000 | - | - | Stock Option (Right to Buy) | |
| Robert J. Hariri | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Sep 2021 | 2,690,079 | 2,690,079 | - | - | Stock Option (Right to Buy) |